Placebo for Ocrelizumab

DRUG2 trials

Sponsors

F. Hoffmann-La Roche AG, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Multiple SclerosisRelapsing-Remitting Multiple Sclerosis

Phase 3

A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Active, not recruitingCTIS2023-506516-40-00

F. Hoffmann-La Roche AGRelapsing-Remitting Multiple Sclerosis

Start: 2022-02-11Target: 94Updated: 2025-10-01

Phase 4

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

RecruitingNCT05285891

National Institute of Allergy and Infectious Diseases (NIAID)Multiple Sclerosis

Start: 2023-01-12End: 2030-11-01Target: 123Updated: 2026-03-20